Literature DB >> 7915626

Prolongation of rat cardiac allograft survival by a monoclonal antibody: anti-rat intercellular adhesion molecule-1.

H Kobayashi1, T Miyano, A Yamataka, T Yamataka, H Yagita, H Eto, Y Ligo, S Tansyo, Y Kojima, T Tamatani.   

Abstract

A mouse monoclonal antibody 1A29, which binds to the rat intercellular adhesion molecule-1 (ICAM-1), was studied for its effect on cardiac allograft survival. Expression of ICAM-1 was detectable only on vascular endothelium in normal heart, but was induced on myocardium associated with interstitial mononuclear cell infiltration during acute rejection. Treatment with monoclonal antibody 1A29 for 10 days after transplantation in 15 rats significantly prolonged allograft survival (mean(s.d.) 18(2) days; P < 0.001), as compared with 15 isotype-matched control monoclonal antibody (mean(s.d.) 10(1) days) recipients. Five-day treatment with monoclonal antibody 1A29, when started at 5 days after transplantation (the time for which acute rejection is ongoing), also significantly extended the survival (mean(s.d.) 12(1) days; P < 0.01) in seven rats. On histological examination, treatment with monoclonal antibody 1A29 reduced the degree of T-cell infiltration of both CD4+ and CD8+ subsets, and greatly reduced myocardial necrosis, vascular injury and intravenous thrombi. These results indicate that an anti-ICAM-1 monoclonal antibody can be used to prevent or treat acute rejection in the rat cardiac allograft model and suggest that human ICAM-1 is an important target for immunosuppression in clinical organ transplantation.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7915626

Source DB:  PubMed          Journal:  Cardiovasc Surg        ISSN: 0967-2109


  1 in total

1.  Specific acceptance of fetal bowel allograft in mice after combined treatment with anti-intercellular adhesion molecule-1 and leukocyte function-associated antigen-1 antibodies.

Authors:  Y Kato; A Yamataka; H Yagita; K Okumura; T Fujiwara; T Miyano
Journal:  Ann Surg       Date:  1996-01       Impact factor: 12.969

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.